Malaria remains one of the most pressing global health challenges, with artemisinin-based combination therapies (ACTs) continuing to provide the foundation for case management. However, the landscape of malaria treatment and prevention is shifting rapidly. Emerging threats such as antimalarial drug resistance (AMDR), evolving funding dynamics, and new therapeutic and preventive tools are changing the future role of artemisinin.

Taking these factors into account, this report, Antimalarial Market Shifts and the Future Role of Artemisinin, provides a comprehensive assessment of the key factors likely to influence ACT demand and market composition over the next decade.

Drawing on literature reviews, expert interviews, and policy insights, the report highlights the continued importance of ACTs in case management, the potential of semisynthetic artemisinin to safeguard ACT supply chains, and the implications of emerging treatment options, such as triple ACTs and non-artemisinin-based combination therapies. In addition, the report aims to complement ongoing global efforts to forecast case management needs, contributing to an improved understanding of malaria market dynamics.